Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AURORA 2: Aurinia Renal Response in Lupus With Voclosporin

Trial Profile

AURORA 2: Aurinia Renal Response in Lupus With Voclosporin

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Voclosporin (Primary)
  • Indications Lupus nephritis
  • Focus Adverse reactions
  • Acronyms AURORA2
  • Sponsors Aurinia Pharmaceuticals
  • Most Recent Events

    • 14 Nov 2019 According to an Aurinia Pharmaceuticals media release, the results from this study is not required for the FDA approval, however, the results will give aluable insights as to the long-term safety and efficacy of voclosporin as a potential new treatment for Lupus nephritis
    • 25 Jun 2018 According to an Aurinia Pharmaceuticals media release, first patients has been enrolled in this extension study.
    • 17 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top